Celcuity (CELC) Is Down 17.4% After FDA Clears First-in-Class REVTORPYK Combo for HR+ Breast Cancer

• In July 2026, Celcuity announced that the FDA approved REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation after at least one line of endocrine therapy in the metastatic setting.
• This approval makes REVTORPYK the only therapy targeting all class I PI3K isoforms and both mTORC1 and mTORC2 complexes in this patient group, backed by VIKTORIA-1 data showing a marked progression-free survival benefit but also a high incidence of stomatitis, rash and metabolic side effects.
• Next, we’ll examine how this first-in-class approval, supported by VIKTORIA-1 progression-free survival results, reshapes Celcuity’s previously pre-approval investment narrative.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Celcuity Investment Narrative Recap

To own Celcuity, you have to believe gedatolisib can move from a single newly approved product to a durable franchise across breast and potentially prostate cancer, while the company manages high cash burn and leverage. The REVTORPYK approval largely resolves the near term regulatory risk in second line HR positive, HER2 negative breast cancer and shifts the key catalyst to real world uptake and payer access, with the biggest risk now that adoption and pricing fall short of expectations.

Among recent announcements, the May 2026 upsized US$500.0 million convertible senior notes deal stands out here. It funded debt repayment and gives Celcuity more room to invest in commercialization and additional trials around REVTORPYK, but it also adds future interest and dilution considerations that sit squarely next to today’s new commercial opportunity as investors evaluate what comes next.

However, investors should also be aware that if gedatolisib uptake is slower than expected in real world practice, Celcuity’s heavy spending and added debt could...

Read the full narrative on Celcuity (it's free!)

Celcuity's narrative projects $817.9 million revenue and $267.5 million earnings by 2029. This implies an earnings increase of about $460 million from -$192.9 million today.

Uncover how Celcuity's forecasts yield a $161.09 fair value, a 76% upside to its current price.

Exploring Other Perspectives

Before this approval, the most bearish analysts were modeling about US$535.0 million of revenue and only US$22.0 million of earnings by 2029, so compared with the view that VIKTORIA 1 success and broad oncologist adoption could transform Celcuity’s prospects, you can see how far apart opinions were and why this new data and approval may lead both camps to revisit their assumptions.

Explore 4 other fair value estimates on Celcuity - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Celcuity research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Celcuity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Celcuity's overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com